Future Trends Of Abiraterone Acetate

May 13, 2026

Leave a message

The development history of abiraterone acetate epitomizes the evolution of China's anti-tumor drugs: original drug monopoly → domestic generic replication → volume-based procurement for affordable access → innovation and upgrading. The national volume-based procurement policy has completely broken the high-price barrier of original branded drugs, making this life-saving medication accessible to patients with advanced prostate cancer. Meanwhile, it has forced pharmaceutical enterprises to shift from a price war to an innovation-driven competition, advancing high-quality development of the industry.

 

In the future, with the launch of innovative dosage forms and accelerated globalization expansion, domestic abiraterone acetate will occupy an important position in the global market, bringing survival hope to more patients worldwide.

 

(I) For Patients: From Sky-High Priced Drugs to Affordable Medication

 

After volume-based procurement, the monthly medication cost dropped from 16,000 yuan to less than 1,000 yuan. With medical insurance reimbursement, patients only pay 200–300 yuan per month out of pocket, eliminating the financial burden entirely. The survival period of advanced prostate cancer patients has extended from 18 months to over 30 months, with a marked improvement in quality of life.

 

(II) For Enterprises: Intensified Generic Drug Homogenization; Innovation Becomes the Key to Breakthrough

 

Generic pharmaceutical companies: The price war has turned white-hot, with profit margins compressed to 5%–10%, leaving small and medium-sized enterprises facing the risk of being phased out. Leading enterprises such as Chia Tai Tianqing and Hengrui Medicine maintain competitiveness through large-scale production and channel expansion to grassroots markets.

 

Innovative original drug enterprises: The patent cliff emerges after patent expiration, forcing brand owners to cut prices or withdraw from the market. Johnson & Johnson has gradually pivoted to innovative drug R&D, including PARP inhibitors and bispecific antibodies, to develop next-generation therapeutic agents for prostate cancer.

 

(III) Future Trends

 

Continued price decline: The renewal of the 3rd national volume-based procurement, combined with provincial alliance procurement, may further lower the monthly price to 500–600 yuan, close to the cost line.

 

Rise of innovative dosage forms: Nanocrystal formulations and sustained-release preparations are gradually replacing conventional tablets to become market mainstream. Fixed-dose combination regimens (abiraterone acetate plus olaparib) have entered clinical trials, expected to deliver synergistic therapeutic effects of 1+1>2.

 

Higher market concentration: Small and medium-sized manufacturers will be eliminated, and market share will concentrate among leading enterprises including Chia Tai Tianqing, Hengrui Medicine and Qilu Pharmaceutical, forming a 3+N competitive landscape.

 

Overseas expansion as a new growth driver: Domestic generic drugs enter the European and U.S. markets via ANDA approval, capturing global generic market share with price advantages. Innovative dosage forms are conducting international multicenter clinical trials simultaneously to accelerate global layout.

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!